Literature DB >> 7573370

Transforming growth factor-beta in human cutaneous leishmaniasis.

A Barral1, M Teixeira, P Reis, V Vinhas, J Costa, H Lessa, A L Bittencourt, S Reed, E M Carvalho, M Barral-Netto.   

Abstract

Transforming growth factor (TGF)-beta has several downregulatory functions on the immune system: inhibition of interleukin-2 receptor induction, decrease of interferon-gamma-induced class II antigen expression, inhibition of macrophage activation, as well as cytotoxic and lymphokine-activated killer cell generation. TGF-beta has also been recognized as an important immunoregulator in murine leishmaniasis, for which it increases susceptibility to disease. In the present study we evaluate the involvement of TGF-beta in human leishmaniasis in vitro and in patients with cutaneous leishmaniasis. Human macrophages produce active TGF-beta after infection by Leishmania amazonensis (480 +/- 44.7 pg/ml; mean +/- SEM), L. donovani chagasi (295 +/- 7.6 pg/ml), or L. braziliensis (196 +/- 15.7 pg/ml). When TGF-beta was added to cultures of human macrophages infected with L. braziliensis it led to an increase of approximately 50% in parasite numbers as compared with untreated cultures. Exogenous TGF-beta added to macrophage cultures was able to reverse the effect of interferon-gamma in controlling Leishmania growth. Even at 100 IU/ml interferon-gamma the presence of TGF-beta increases the number of intracellular parasites. On the other hand, TNF-alpha at high concentration (100 IU/ml) totally blunts the suppressive effect of TGF-beta. Immunostaining for TGF-beta was observed in the dermis, produced by fibroblasts and occasionally by inflammatory cells in the biopsies from human leishmaniasis lesions, being present in most of the biopsies taken from patients with early cutaneous leishmaniasis (less than 2 months of ulcer development) and in cases of active mucosal leishmaniasis. Taken together these observations suggest an important role for TGF-beta in human leishmaniasis, with its production by infected macrophages being probably related to parasite establishment in the early stages of the disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573370      PMCID: PMC1871026     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

1.  Evaluation of the micro enzyme-linked immunosorbent assay (ELISA) for antibodies in American visceral leishmaniasis: antigen selection for detection of infection-specific responses.

Authors:  R Badaró; S G Reed; A Barral; G Orge; T C Jones
Journal:  Am J Trop Med Hyg       Date:  1986-01       Impact factor: 2.345

2.  Diffuse cutaneous leishmaniasis in Ethiopia. I. The clinical and histological features of the disease.

Authors:  A D Bryceson
Journal:  Trans R Soc Trop Med Hyg       Date:  1969       Impact factor: 2.184

Review 3.  Mucosal leishmaniasis ("espundia" Escomel, 1911).

Authors:  P D Marsden
Journal:  Trans R Soc Trop Med Hyg       Date:  1986       Impact factor: 2.184

4.  Deactivation of macrophages by transforming growth factor-beta.

Authors:  S Tsunawaki; M Sporn; A Ding; C Nathan
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

5.  Polar and subpolar diffuse cutaneous leishmaniasis in Brazil: clinical and immunopathologic aspects.

Authors:  A Barral; J M Costa; A L Bittencourt; M Barral-Netto; E M Carvalho
Journal:  Int J Dermatol       Date:  1995-07       Impact factor: 2.736

6.  Production and characterization of species-specific monoclonal antibodies against Leishmania donovani for immunodiagnosis.

Authors:  C L Jaffe; E Bennett; G Grimaldi; D McMahon-Pratt
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

7.  Transforming growth factor-beta 1 modulates the expression of class II histocompatibility antigens on human cells.

Authors:  C W Czarniecki; H H Chiu; G H Wong; S M McCabe; M A Palladino
Journal:  J Immunol       Date:  1988-06-15       Impact factor: 5.422

8.  Selection of a skin test antigen for American visceral leishmaniasis.

Authors:  S G Reed; R Badaró; H Masur; E M Carvalho; R Lorenco; A Lisboa; R Teixeira; W D Johnson; T C Jones
Journal:  Am J Trop Med Hyg       Date:  1986-01       Impact factor: 2.345

9.  Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.

Authors:  J J Mulé; S L Schwarz; A B Roberts; M B Sporn; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

10.  Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.

Authors:  G E Ranges; I S Figari; T Espevik; M A Palladino
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

View more
  26 in total

1.  Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro.

Authors:  C Brodskyn; S M Beverley; R G Titus
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

2.  Transforming growth factor beta 1 production by CD4+ CD25+ regulatory T cells in peripheral blood mononuclear cells from healthy subjects stimulated with Leishmania guyanensis.

Authors:  A Kariminia; E Bourreau; H Pascalis; P Couppié; D Sainte-Marie; F Tacchini-Cottier; P Launois
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Therapeutic failure in American cutaneous leishmaniasis is associated with gelatinase activity and cytokine expression.

Authors:  A C Maretti-Mira; M P de Oliveira-Neto; A M Da-Cruz; M P de Oliveira; N Craft; C Pirmez
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

Review 4.  The Interactome of the Glucocorticoid Receptor and Its Influence on the Actions of Glucocorticoids in Combatting Inflammatory and Infectious Diseases.

Authors:  Ioanna Petta; Lien Dejager; Marlies Ballegeer; Sam Lievens; Jan Tavernier; Karolien De Bosscher; Claude Libert
Journal:  Microbiol Mol Biol Rev       Date:  2016-05-11       Impact factor: 11.056

5.  TGF-β inhibits IL-7-induced proliferation in memory but not naive human CD4+ T cells.

Authors:  Thao P Nguyen; Scott F Sieg
Journal:  J Leukoc Biol       Date:  2017-06-06       Impact factor: 4.962

6.  Transforming growth factor beta and immunosuppression in experimental visceral leishmaniasis.

Authors:  V Rodrigues; J Santana da Silva; A Campos-Neto
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

7.  Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis.

Authors:  Annette Ives; Catherine Ronet; Florence Prevel; Giulia Ruzzante; Silvia Fuertes-Marraco; Frederic Schutz; Haroun Zangger; Melanie Revaz-Breton; Lon-Fye Lye; Suzanne M Hickerson; Stephen M Beverley; Hans Acha-Orbea; Pascal Launois; Nicolas Fasel; Slavica Masina
Journal:  Science       Date:  2011-02-11       Impact factor: 47.728

Review 8.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

9.  Ascorbate peroxidase from Leishmania major controls the virulence of infective stage of promastigotes by regulating oxidative stress.

Authors:  Swati Pal; Subhankar Dolai; Rajesh K Yadav; Subrata Adak
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

10.  Effects of tropism and virulence of Leishmania parasites on cytokine production by infected human monocytes.

Authors:  A Meddeb-Garnaoui; H Zrelli; K Dellagi
Journal:  Clin Exp Immunol       Date:  2008-11-20       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.